The Future of Pharma Markets: Looking Ahead to 2023 - Immediate Opportunities & Threats, , Opportunities 5 Year from Now, Clinical Trials
06 juin 2023 04h18 HE
|
Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Future of Pharma - Looking Ahead to 2023" report has been added to ResearchAndMarkets.com's offering.This report provides a summary of the near and...
Technology Advances in Senolytics 2023: Innovative Drug Development Culture Working to Prolong Health Spans and Eliminate Aging Cells
26 mai 2023 05h53 HE
|
Research and Markets
Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "Technology Advances in Senolytics" report has been added to ResearchAndMarkets.com's offering. Senolytics is a relatively new field of development...
The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022: Roche Ranked 1st Overall with Novo Nordisk in 2nd and Pfizer in 3rd
12 janv. 2023 08h53 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Italy Edition: The Views of 103 Italian Patient Groups" report has been added to...
Patient Perspective of 151 German Patient Groups on the Corporate Reputation of Pharma, 2021-2022: Ranking of 24 Companies
12 janv. 2023 06h38 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - Germany Edition - The Views of 151 German Patient Groups" report has been added...
Views of 258 Neurology Patient Groups on the Corporate Reputation of Pharma in 2022: Roche Ranked 1st, Novartis Ranked 2nd and Biogen Ranked 3rd
12 janv. 2023 06h28 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2022 - The Patient Perspective - Neurology Edition: The Views of 258 Neurology Patient Groups" report has been...
The Views of 300 Asian Patient Groups on the he Corporate Reputation of Pharma, 2021-2022: Overall Gilead Sciences Ranked 1st, Pfizer Ranked 2nd, and ViiV Healthcare Ranked 3rd
12 janv. 2023 06h23 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Asia Edition - The Views of 300 Asian Patient Groups" report has been added to ...
Corporate Reputation of Pharma Companies in Spain, 2020 vs 2021: ViiV Healthcare Ranked 1st, Janssen Ranked 2nd, Gilead Sciences Ranked 3rd
09 janv. 2023 08h48 HE
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Spain Edition: The Views of 154 Spanish Patient Groups" report has been added to...
Autoimmune Patient Perspective on the Corporate Reputation of Pharma Companies, 2021-2022: Focus on Innovation and Treatments, COVID-19, & Pricing and Access to Medicines
09 janv. 2023 08h28 HE
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - Autoimmune Edition - The Views of 293 Patient Groups (138 of these respondent...
Patient Perspective of the Corporate Reputation of Pharma in 2021-2022: Focus on Chiesi Farmaceutici, AbbVie, Bayer, Eli Lilly, GSK, Merck, Mylan, Novartis, Pfizer, Roche, Sanofi, Teva Among Others
09 janv. 2023 08h23 HE
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Respiratory Edition - The Views of 121 Respiratory Conditions Patient Groups"...
The Corporate Reputation of Pharma Companies in Canada, 2021-2022: AbbVie, Roche, BMS, Sanofi, Pfizer, Merck, Bayer and Amgen Made the Biggest Rises
09 janv. 2023 08h18 HE
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added...